dbff498b4aa6.jpgIn the guide, TAG argues that TB treatment must be shorter, simpler, less toxic and more tolerable and affordable.

The think tank has published the guide in the hopes that activists can contribute to the development and uptake of improved TB treatment by calling attention to research, quality of medications, and access priorities.

The guide provides a brief summary of safety and efficacy data for those drugs currently in use for TB, many of which have been approved for other diseases but are used off-label for TB. It highlights enrolling paediatric trials for the TB drug delamanid in South Africa as well as the country’s use of terizidone as a last report drug for drug-resistant TB.

As of March 2014, delamanid had not yet been registered for use in South Africa.

Download the guide: An Activist’s Guide to Tuberculosis Drugs